• Hepatitis C in Brazil: Overview and challenges in the light of the COVID-19 pandemic, technical report, 2021.
• Hepatite C no Brasil: Panorama atual e desafios em face à pandemia de COVID-19, nota técnica, 2021.
• FGV Sumário Executivo, 2022
• FGV Relatório 01: Governança do programa de hepatites virais, 2022
• FGV Relatório 02: Trajetória da assistência farmacêutica para hepatite C no SUS, 2022
• Opinion article 01: Para avançar na eliminação da hepatite C no Brasil, é preciso atualizar os bancos de dados sobre a doença
• Opinion article 02: Enfrentamento à hepatite C no Brasil
• Opinion article 03: Três Perguntas: Helena de Moraes Achcar comenta a importância de parcerias na negociação política em saúde
• Research article 01: Dried blood spot sampling as an alternative for the improvement of hepatitis B and C diagnosis in key populations (DOI: 10.4254/wjh.v13.i4.504)
• Research article 02: Performance of HCV Antigen Testing for the Diagnosis and Monitoring of Antiviral Treatment
• Research article 03: Persistently high hepatitis C rates in haemodialysis patients in Brazil [a systematic review and meta‑analysis]
• Conference presentation 01: Arantes, L. and Fonseca, E. Enfrentamento à Hepatite C no Brasil e na Espanha, XLIV Encontro da Associação Nacional de Pós-Graduação e Pesquisa em Administração, online (2020)
• Conference presentation 02: Arantes, L. Fonseca, E., Shadlen, K. Recentralizing Drug Procurement in a Context of Decentralized Health System: The Case of Hepatitis C Drugs in Brazil. 5th International Conference on Public Policy, Barcelona (2021)
• Conference presentation 03: Davidian, A. and Fonseca, E. The governance of Brazilian response to viral hepatitis. 3rd International Workshops on Public Policy, Budapest, 2020
•Conference presentation 04: Achcar, H., and Fonseca, E. The politics and governance of drug production in public-private partnerships: Brazil’s response to hepatitis C. Red para el Estudio de la Economía Política de América Latina Annual Meeting, Buenos Aires, 2022.